Combining the disparate databases used to detect potential issues with drugs, vaccines and other products into a single dashboard will enhance their utility and cut costs, the agency said.

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

Ugur Sahin and Özlem Türeci, who directed the COVID vaccine maker’s rise to prominence, will helm an as-yet-unnamed company ...

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved ...

Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or ...

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain ...

Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.

Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many ...

The therapy, mezigdomide, is part of group of medicines the pharma sees as successors to its lucrative multiple myeloma drugs ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

The Kanakee project builds on the company’s efforts to increase its U.S. footprint, where it has already spent more than $3 ...

Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine ...